[[lncRNA]]s [[ZFAS1]] and [[MALAT1]] were significantly upregulated (p < 0.05), whereas lncRNAs [[LINC00261]] and [[LINC01619]] were significantly downregulated in [[SAH]] patients with [[CVS]] (p < 0.05) compared to SAH patients without CVS. Pan et al. applied this lncRNA signature to retrospectively predict CVS in SAH patients (n = 38 for SAH patients without CVS, and n = 27 for SAH patients with CVS). The 4-lncRNA signature was found to be predictive in >40% of samples and the 2-lncRNA comprising MALAT1 and LINC01619 accurately predicted CVS in ∼90% cases. These results are initial steps toward personalized management of SAH patients in clinics and provide novel [[CSF biomarkers]] that can substantially improve the clinical management of SAH patients
((Pan CY, Tian M, Zhang LL, et al. lncRNA Signature for Predicting Cerebral Vasospasm in Patients with SAH: Implications for Precision Neurosurgery [published online ahead of print, 2020 Jul 25]. Mol Ther Nucleic Acids. 2020;21:983-990. doi:10.1016/j.omtn.2020.07.028)).